DUBLIN-- (BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of a patient case series at the American College of Rheumatology (ACR) Annual Meeting illustrating ...

In a phase 2 trial, firsekibart — an IL-1 beta antibody — outperforms colchicine in preventing acute gout flares over 12 weeks in patients with gouty arthritis initiating urate-lowering therapy.

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data that indicate KRYSTEXXA (pegloticase) injection with weekly oral methotrexate effectively treats uncontrolled ...

-- Initial data from investigator-initiated TRIPLE study shows infusion reactions occurred in less than 1 percent of infusions -- -- Analyses further support the efficacy and safety of KRYSTEXXA -- ...

-- Randomized controlled trial will add to results from prior open-label trial and in-practice case series -- DUBLIN--(BUSINESS WIRE)-- Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the ...